Drug name: Gemcitabine + Dimethylamino parthenolide


Related CSCTT Targets

NFκB1 [ref.1]P19838
NFκB2 [ref.1]Q00653

Gemcitabine

Cas.no PubChem ID
95058-81-4 60750
Known Target
DNA
Ribonucleoside-diphosphate reductase large subunitP23921
Thymidylate synthaseP04818
UMP-CMP kinaseP30085
Structure
...
Introduction
Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar® by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumor growth, as new nucleosides cannot be attached to the “faulty” nucleoside, resulting in apoptosis (cellular “suicide”). Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It is being investigated for use in oesophageal cancer, and is used experimentally in lymphomas and various other tumor types.

Dimethylamino parthenolide

Cas.no PubChem ID
1070780-82-3 24205116
Known Target
Nuclear factor NF-kappa-B p105 subunitP19838
Nuclear factor NF-kappa-B p100 subunitQ00653
Structure
...
Introduction
Dimethylaminoparthenolide (DMAPT) is a water soluble parthenolide analog with preclinical activity in hematologic malignancies.

Reference

  • [1] Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. Yip-Schneider, M. T., et al. (2013).BMC Cancer. 13:194.
    23590467. [ 23590467 ]

Back to top